CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01% Market Closed
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Investor Relations

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Dr. Alexander Zehnder M.B.A., M.D.
CEO, MD & Member of Management Board
No Bio Available
Dr. Malte Greune Ph.D.
COO, Member of Management Board & MD
No Bio Available
Dr. Myriam Mendila M.D.
Chief Scientific Officer, Head of R&D, MD & Member of the Management Board
No Bio Available
Dr. Ulrike Gnad-Vogt M.D., Ph.D.
Senior VP & Area Head of Oncology
No Bio Available
Mr. Axel-Sven Malkomes
Chief Financial Officer
No Bio Available
Dr. Sarah Fakih
Vice President Corporate Communications & Investor Relations
No Bio Available
Mr. Marco Rau L.L.M., Ph.D.
General Counsel
No Bio Available
Mr. Thorsten Schuller
Head of Corporate Communications
No Bio Available
Slavica Stevanovic-Heck
Head of Human Resources
No Bio Available
Dr. Patrick Baumhof
Senior Vice President of Technology
No Bio Available

Contacts

Address
BADEN-WUERTTEMBERG
Tuebingen
Friedrich-Miescher-Str. 15
Contacts
+49707198830.0
www.curevac.com